Market News

CASI Pharmaceuticals, Inc. (CASI) Reaches $3.85 After 4.00% Down Move; INDUSTRIAL AND COMMERCIAL BANK OF CHINA (IDCBF) Shorts Raised By 1.81%

The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a huge mover today! The stock decreased 1.53% or $0.06 during the last trading session, reaching $3.85. About 180,916 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since March 21, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.The move comes after 7 months negative chart setup for the $269.13 million company. It was reported on Mar, 21 by We have $3.70 PT which if reached, will make NASDAQ:CASI worth $10.77 million less.

INDUSTRIAL AND COMMERCIAL BANK OF CHINA (OTCMKTS:IDCBF) had an increase of 1.81% in short interest. IDCBF’s SI was 9.91M shares in March as released by FINRA. Its up 1.81% from 9.74M shares previously. With 299,600 avg volume, 33 days are for INDUSTRIAL AND COMMERCIAL BANK OF CHINA (OTCMKTS:IDCBF)’s short sellers to cover IDCBF’s short positions. The SI to INDUSTRIAL AND COMMERCIAL BANK OF CHINA’s float is 0.01%. The stock increased 1.16% or $0.01 during the last trading session, reaching $0.87. About 2,000 shares traded. Industrial and Commercial Bank of China Limited (OTCMKTS:IDCBF) has 0.00% since March 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report earnings on March, 30. They expect $-0.03 EPS, up 40.00% or $0.02 from last year’s $-0.05 per share. After $-0.03 actual EPS reported by CASI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 1.9 in 2017 Q3. Its up 0.76, from 1.14 in 2017Q2. It improved, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported. Morgan Stanley holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 1,157 shares. Northern Corporation invested in 0% or 31,034 shares. 38,315 are owned by Geode Mngmt Limited Com. Natl Bank Of America Corp De accumulated 1,144 shares. Moors & Cabot stated it has 26,053 shares. Next Gp Incorporated, Texas-based fund reported 2 shares. Guggenheim Capital Ltd Liability reported 12,242 shares stake. California Pub Employees Retirement holds 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) or 136,518 shares. Everett Harris And Ca has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 10,002 shares. Blackrock reported 291,106 shares stake. Raymond James Fincl Services Advsrs Inc reported 0% stake. 17,572 were accumulated by Royal Commercial Bank Of Canada. 489,984 are held by Wellington Shields Comm Ltd Liability Corporation. 358,972 are owned by Vanguard Grp Incorporated. Moreover, Renaissance Technology Ltd Llc has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 112,900 shares.

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc has $4.5 highest and $2.0 lowest target. $4.25’s average target is 10.39% above currents $3.85 stock price. CASI Pharmaceuticals Inc had 5 analyst reports since October 29, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright on Thursday, October 29 with “Buy”. On Monday, August 14 the stock rating was maintained by Maxim Group with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, January 16 report. The company was initiated on Thursday, September 22 by Maxim Group.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $269.13 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Leave a Reply

Your email address will not be published. Required fields are marked *